PALISADE BIO, INC. 8-K

What Happened
Palisade Bio, Inc. (PALI) filed an 8-K reporting that on March 30, 2026 it entered into a master services agreement (MSA) with Iterative Scopes, Inc. d/b/a Iterative Health (IH) to help expedite enrollment for an expected Phase 2 study of PALI-2108 in moderate to severe Ulcerative Colitis (UC). On March 27, 2026 the company sold 1,536,885 shares of common stock to an affiliate of IH for $3.0 million, at $1.952 per share (the five‑day average closing price prior to closing). The share sale was conducted in a private transaction relying on Section 4(a)(2) of the Securities Act.

Key Details

• MSA date: March 30, 2026; counterparty: Iterative Scopes, Inc. d/b/a Iterative Health.
• Equity financing: 1,536,885 shares issued on March 27, 2026 for total proceeds of $3.0 million.
• Price per share: $1.952 (five‑day Nasdaq Capital Market average prior to closing).
• Securities treatment: Shares sold in a transaction exempt from registration under Section 4(a)(2).

Why It Matters
This filing shows Palisade Bio secured both a commercial collaboration and immediate funding tied to advancing its PALI-2108 Phase 2 UC program. The MSA could help accelerate patient enrollment — a common bottleneck for clinical trials — while the $3.0M equity infusion provides near-term capital. Investors should note the share issuance increases outstanding shares (potential dilution) and the company’s forward-looking plans remain subject to risks disclosed in its recent Form 10-K.